| Autor: |
Moreau, P. Dimopoulos, M.A. Richardson, P.G. Siegel, D.S. Cavo, M. Corradini, P. Weisel, K. Delforge, M. O'Gorman, P. Song, K. Chen, C. Bahlis, N. Oriol, A. Hansson, M. Kaiser, M. Anttila, P. Raymakers, R. Joao, C. Cook, G. Sternas, L. Biyukov, T. Slaughter, A. Hong, K. Herring, J. Yu, X. Zaki, M. San-Miguel, J. |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Popis: |
Objectives: Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management. Methods: This analysis included 1088 patients who received ≥ 2 prior therapies, including lenalidomide and bortezomib, and progressed ≤ 60 days of last therapy. Patients received 28-day cycles of pomalidomide 4 mg/day on days 1-21 and low-dose dexamethasone 40 mg (20 mg if aged > 75 years) weekly until disease progression or unacceptable toxicity. Thromboprophylaxis was required. Results: The most common grade 3/4 AEs were neutropenia (56.2%), anemia (32.3%), and thrombocytopenia (25.8%), which occurred within the first few cycles of treatment. Grade 3/4 infections occurred in 33.7% patients, of whom 13.9% had pneumonia, and 40.3% had neutropenia. Pomalidomide dose reductions or interruptions were reported in 24.2% and 66.0% of patients, respectively. AEs were managed by dose modifications and/or supportive care. Conclusions: Pomalidomide plus low-dose dexamethasone showed an acceptable safety profile, and AEs were well managed according to study protocols and established guidelines. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
